A theoretical entropy score as a single value to express inhibitor selectivity

BMC Bioinformatics

Volumn 12, Issue , 2011, Pages

  Uitdehaag, Joost C M ^a   Zaman, Guido J R ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPOUND SELECTIVITY; DRUG DISCOVERY PROCESS; HIGH-THROUGHPUT SCREENING; INHIBITOR SELECTIVITY; KINASE INHIBITORS; MOLECULAR MECHANISM; QUANTITATIVE MEASURES; SELECTIVE LIGANDS;

ENZYMES;

ENTROPY;

CELL RECEPTOR; LIGAND; PROTEIN KINASE INHIBITOR;

ARTICLE; CHEMISTRY; COMPUTER PROGRAM; DRUG DEVELOPMENT; ENTROPY; HIGH THROUGHPUT SCREENING; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; METHODOLOGY;

DRUG DISCOVERY; ENTROPY; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LIGANDS; PROTEIN KINASE INHIBITORS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SOFTWARE DESIGN;

EID: 79953837902     PISSN: None     EISSN: 14712105     Source Type: Journal    
DOI: 10.1186/1471-2105-12-94     Document Type: Article

References (53)

1. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of some commonly used protein kinase inhibitors. Biochem J 2000, 351(Pt1):95-105. 10.1042/0264-6021:3510095, 1221339, 10998351.
2. Vieth M, Higgs RE, Robertson DH, Shapiro M, Gragg EA, Hemmerle H. Kinomics - structural biology and chemogenomics of kinase inhibitors and targets. Biochem Biophys Acta 2004, 1697(1-2):243-257.
3. Bain J, Plater L, Elliott M, Shapiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur JSC, Alessi DR, Cohen P. The selectivity of protein kinase inhibitors: a further update. Biochem J 2007, 408(3):297-315. 10.1042/BJ20070797, 2267365, 17850214.
4. Fedorov O, Marsden B, Pogagic V, Rellos P, Müller S, Bullock AN, Schwaller J, Sundström M, Knapp S. A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci USA 2007, 104(51):20523-20528. 10.1073/pnas.0708800104, 2154464, 18077363.
5. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT, Faraoni R, Floyd M, Hunt JP, Lockhart DJ, Milanov ZV, Morrison MJ, Pallares G, Patel HK, Pritchard S, Wodicka LM, Zarrinkar PP. A quantitative analysis of kinase inhibitor selectivity. Nature Biotechnol 2008, 26(1):127-132.
6. Bamborough P, Drewry D, Harper G, Smith GK, Schneider K. Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. J Med Chem 2008, 51(24):7898-7914. 10.1021/jm8011036, 19035792.
7. Smyth LA, Collins I. Measuring and interpreting the selectivity of protein kinase inhibitors. J Chem Biol 2009, 2(3):131-151. 10.1007/s12154-009-0023-9, 2725273, 19568781.
8. Heilker R, Wolff M, Tautermann CS, Bieler M. G-protein-coupled receptor focused drug discovery using a target class platform approach. Drug Discov Today 2009, 14(5-6):231-240. 10.1016/j.drudis.2008.11.011, 19121411.
9. Wilkinson JM, Hayes S, Thompson D, Whitney P, Bi K. Compound profiling using a panel of steroid hormone receptor cell-based assays. J Biomol Screen 2008, 13(8):755-765. 10.1177/1087057108322155, 18753690.
10. Sciabola S, Stanton RV, Wittkop S, Wildman S, Moshinsky D, Potluri S, Xi H. Predicting kinase selectivity profiles using free-wilson QSAR analysis. J Chem Inf Model 2008, 48(9):1851-1867. 10.1021/ci800138n, 18717582.
11. Sheridan RP, Nam K, Maiorov VN, McMasters DR, Cornell WD. QSAR models for predicting the similarity in binding profiles for pairs of protein kinases and the variation of models between experimental data sets. J Chem Inf Model 2009, 49(8):1974-1985. 10.1021/ci900176y, 19639957.
12. Brandt P, Jensen AJ, Nilsson J. Small kinase assay panels can provide a measure of selectivity. BioOrg Med Chem Letters 2009, 19(20):5861-5863.
13. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 2002, 298(5600):1912-1934. 10.1126/science.1075762, 12471243.
14. Fabian MA, Biggs WH, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG, Carter TA, Ciceri P, Edeen PT, Floyd M, Ford JM, Galvin M, Gerlach JL, Grotzfeld RM, Herrgard S, Insko DE, Insko MA, Lai AG, Lélias JM, Mehta SA, Milanov ZV, Velasco AM, Wodicka LM, Patel HK, Zarrinkar PP, Lockhart DJ. A small molecule-kinase interaction map for clinical kinase inhibitors. Nature Biotechnol 2005, 23(3):329-336.
15. Graczyk P. Gini coefficient: a new way to express kinase selectivity against a family of kinases. J Med Chem 2007, 50(23):5773-5779. 10.1021/jm070562u, 17948979.
16. Cheng AC, Eksterowicz J, Geuns-Meyer S, Sun Y. Analysis of kinase inhibitor selectivity using a thermodynamics-based partition index. J Med Chem 2010, 53(11):4502-4510. 10.1021/jm100301x, 20459125.
17. Shannon CE. A mathematical theory of communication. The Bell Systems Technical J 1948, 27:379-423.
18. Atkins P, de Paula J. Atkins' Physical Chemistry 1970, Oxford University Press: Oxford.
19. Cheng Y, Prusoff WH. Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 1973, 22(23):3099-3108. 10.1016/0006-2952(73)90196-2, 4202581.
20. Knight ZA, Shokat KM. Features of selective kinase inhibitors. Chem Biol 2005, 12(6):621-637. 10.1016/j.chembiol.2005.04.011, 15975507.
21. Roman DL, Talbot JN, Roof RA, Sunahara RK, Traynor JR, Neubig RR. Identification of small-molecule inhibitors of RGS4 using a high-troughput flow cytometry protein interaction assay. Mol Pharmacol 2006, 71(1):169-175. 10.1124/mol.106.028670, 17012620.
22. Inman GJ, Nicolás FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, Laping NJ, Hill CS. SB-431542 is a potent and specific inhibitor of transforming growth factor-β superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 2002, 62(1):65-74. 10.1124/mol.62.1.65, 12065756.
23. Kelly LM, Yu JC, Boulton CL, Apatira M, Li J, Sullivan CM, Williams I, Amaral SM, Curley DP, Duclos N, Neuberg D, Scarborough RM, Pandey A, Hollenbach S, Abe K, Lokker NA, Gilliland DG, Giese NA. CT53518, a novel selective Flt3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell 2002, 1(5):421-432. 10.1016/S1535-6108(02)00070-3, 12124172.
24. Hennequin LF, Stokes ES, Thomas AP, Johnstone C, Plé PA, Ogilvie DJ, Dukes M, Wedge SR, Kendrew J, Curwen JO. Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J Med Chem 2002, 45(6):1300-1312. 10.1021/jm011022e, 11881999.
25. Liu Y, Gray NS. Rational design of inhibitors that bind to inactive kinase conformations. Nature Chem Biol 2006, 2(7):358-364.
26. Simard JR, Klüter S, Grütter C, Getlik M, Rabiller M, Rode HB, Rauh D. A new screening assay for allosteric inhibitors of Src. Nature Chem Biol 2009, 5(6):395-396.
27. Wan PTC, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R. Cancer Genome Project Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004, 116(6):855-867. 10.1016/S0092-8674(04)00215-6, 15035987, Cancer Genome Project.
28. Vajpai N, Strauss A, Fendrich G, Cowan-Jacob SW, Manley PW, Grzesiek S, Jahnke W. Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib. J Biol Chem 2008, 283(26):18292-18302. 10.1074/jbc.M801337200, 18434310.
29. Meyers MJ, Pelc M, Kamtekar S, Day J, Poda GI, Hall MK, Michener ML, Reit BA, Mathis KJ, Pierce BS, Parikh MD, Mischke DA, Long SA, Parlow JJ, Anderson DR, Thorarensen A. Structure-based drug design enables conversion of a DFG-in binding CSF-1R kinase inhibitor to a DFG-out binding mode. BioOrg Med Chem Letters 2010, 20(5):1543-1547.
30. Pargellis C, Tong L, Churchill L, Cirillo PF, Gilmore T, Graham AG, Grob PM, Hickey ER, Moss N, Pav S, Regan J. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nature Struct Biol 2002, 9(4):268-272. 10.1038/nsb770, 11896401.
31. Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, Dickerson SH, Ellis B, Pennisi C, Horne E, Lackey K, Alligood KJ, Rusnak DW, Gilmer TM, Shewchuk L. A unique structure of epidermal growth factor receptor bound to GW572016 (lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 2004, 64(18):6652-6659. 10.1158/0008-5472.CAN-04-1168, 15374980.
32. Fischmann TO, Smith CK, Mayhood TW, Meyers JE, Reichert P, Mannarino A, Carr D, Zhu H, Wong J, Yang RS, Le HV, Madison VS. Crystal structures of MEK1 binary and ternary complexes with nucleotides and inhibitors. Biochemistry 2009, 48(12):2661-2674. 10.1021/bi801898e, 19161339.
33. Fitzgerald CE, Patel SB, Becker JW, Cameron PM, Zaller D, Pikounis VB, O'Keefe SJ, Scapin G. Structural basis for p38α MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity. Nature Struct Biol 2003, 10(9):764-769. 10.1038/nsb949, 12897767.
34. Johnson LN. Protein kinase inhibitors: contributions from structure to clinical compounds. Q Rev Biophysics 2009, 42(1):1-40.
35. Hermkens PH, Kamp S, Lusher S, Veeneman GH. Non-steroidal steroid receptor modulators. IDrugs 2006, 9(7):488-494.
36. Egea PF, Klaholz BP, Moras D. Ligand-protein interaction in nuclear receptors of hormones. FEBS Letters 2000, 476(1-2):62-67. 10.1016/S0014-5793(00)01672-0, 10878252.
37. Nettles KW, Sun J, Radek JT, Sheng S, Rodriguez L, Katzenellenbogen JA, Katzenellenbogen BS, Greene GL. Allosteric control of ligand selectivity between estrogen receptors α and β. Mol Cell 2004, 13(3):317-327. 10.1016/S1097-2765(04)00054-1, 14967140.
38. Raaijmakers HC, Versteegh JE, Uitdehaag JCM. The X-ray structure of RU486 bound to the progesterone receptor in a destabilized agonistic conformation. J Biol Chem 2009, 284(9):19572-19579. 10.1074/jbc.M109.007872, 2740583, 19372222.
39. Martinez L, Nascimento AS, Nunes FM, Phillips K, Aparicio R, Dias SM, Figueira AC, Lin JH, Nguyen P, Apriletti JW, Neves FAR, Baxter JD, Webb P, Skaf MS, Polikarpov I. Gaining ligand selectivity in thyroid hormone receptors via entropy. Proc Natl Acad Sci USA 2009, 106(49):20717-20722. 10.1073/pnas.0911024106, 2791634, 19926848.
40. Togashi M, Borngraeber S, Sandler B, Fletterick RJ, Webb P, Baxter JD. Conformational adaptation of nuclear receptor ligand binding domains to agonists: potential for novel approaches to ligand design. J Steroid Biochem Mol Biol 2005, 93(2-5):127-137. 10.1016/j.jsbmb.2005.01.004, 15860255.
41. Bourguet W, Vivat V, Wurtz JM, Chambon P, Gronemeyer H, Moras D. Crystal structure of a heterodimeric complex of RAR and RXR ligand-binding domains. Mol Cell 2000, 5(2):289-298. 10.1016/S1097-2765(00)80424-4, 10882070.
42. Fradera X, Vu D, Nimz O, Skene R, Hosfield D, Wynands R, Cooke AJ, Haunsø A, King A, Bennett DJ, McGuire R, Uitdehaag JCM. X-ray structures of the LXRα LBD in its homodimeric form and implication for heterodimer signaling. J Mol Biol 2010, 399(1):120-132. 10.1016/j.jmb.2010.04.005, 20382159.
43. Cornell W, Nam K. Steroid hormone binding receptors: application of homology modeling, induced fit docking, and molecular dynamics to study structure function relationships. Curr Top Med Chem 2009, 9(9):844-853. 10.2174/156802609789207109, 19754398.
44. Nabuurs SB, Wagener M, de Vlieg J. A flexible approach to induced fit docking. J Med Chem 2007, 50(26):6507-6518. 10.1021/jm070593p, 18031000.
45. Knight ZA, Lin H, Shokat KM. Targeting the cancer kinome through polypharmacology. Nature Rev Cancer 2010, 10(2):130-137.
46. Morphy R, Rankovic Z. Designing multiple ligands - medicinal chemistry strategies and challenges. Curr Pharm Design 2009, 15(6):587-600.
47. Hopkins A. Network pharmacology: the next paradigm in drug discovery. Nature Chem Biol 2008, 4(11):682-690.
48. Robinson D, Sherman W, Farid R. Understanding kinase selectivity through energetic analysis of binding site waters. Chem Med Chem 2010, 5(4):618-627.
49. Scapin G. Protein kinase inhibition: different approaches to selective inhibitor design. Curr Drug Targets 2006, 7(11):1443-1454.
50. Raynaud FI, Eccles S, Clarke PA, Hayes A, Nutley B, Alix S, Henley A, Di-Stefano F, Ahmad Z, Guillard S, Bjerke LM, Kelland L, Valenti M, Patterson L, Gowan S, de Haven Brandon A, Hayakawa M, Kaizawa H, Koizumi T, Ohishi T, Patel S, Saghir N, Parker P, Waterfield M, Workman P. Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res 2007, 67(12):5840-5850. 10.1158/0008-5472.CAN-06-4615, 17575152.
51. Yang Y, Chen H, Nilsson I, Muresan S, Engkvist O. Investigation of the relationship between topology and selectivity for druglike molecules. J Med Chem 2010, 53(21):7709-7714. 10.1021/jm1008456, 20942392.
52. Peters JU, Schnider P, Mattei P, Kansy M. Pharmacological promiscuity: dependence on compound properties and target specificity in a set of recent Roche compounds. Chem Med Chem 2009, 4(4):680-686.
53. Azzaoui K, Hamon J, Faller B, Whitebread S, Jacoby E, Bender A, Jenkins JL, Urban L. Modelling promiscuity based on in vitro safety pharmacology data. Chem Med Chem 2007, 2(6):874-880.